← All products

Reusable dual-chamber platform

Reusable Dual-Chamber Pen for Lyophilized Drug Reconstitution

A repeat-use pen body with a replaceable dual-chamber cartridge for in-pen reconstitution projects.

Cartridge capacity
4 mL dual-chamber cartridge
Dose range
0.01–0.60 mL
Dose increment
0.01 mL
Device lifecycle
Reusable pen body
Nominal cartridge capacity and quoted mechanical dose settings are shown for this configuration. Final cartridge fit, dose accuracy and drug–device compatibility require project-specific confirmation and testing.

Product overview

This reusable dual-chamber injection-pen platform combines a repeat-use pen body with a replaceable, project-matched medicine cartridge. It is intended for technical evaluation when two compatible components need to remain separated during storage and be reconstituted inside the cartridge before injection.

Partner and evidence boundary

Penacta coordinates this sourced platform with a manufacturing partner. Published information supports early B2B screening; cartridge fit, operating sequence, performance and final suitability must be confirmed for the actual project.

Key product features

  • Reusable pen body with a replaceable dual-chamber cartridge
  • Electroplated plastic housing with a metallic-look finish; not a metal shell
  • Separated storage and in-cartridge reconstitution
  • Fixed-dose or variable-dose project discussion
  • Color, surface finish, logo, labeling and packaging options

Technical specifications

The quoted configuration is shown below. Cartridge fit, dose accuracy, delivered volume and drug–device compatibility remain subject to project-specific verification.

Device typeReusable dual-chamber cartridge pen
Device lifecycleRepeat-use pen body with replaceable cartridge
Housing materialElectroplated plastic housing (not metal)
Cartridge capacity4 mL dual-chamber cartridge (nominal specification)
Formulation directionLyophilized drug plus diluent, or compatible liquid-liquid system
Reconstitution directionIn-pen activation and mixing before injection
Dose range0.01–0.60 mL
Dose increment0.01 mL
Suggested diluent inputApprox. 1.05–1.10 mL (factory estimate; formulation-dependent)
Estimated usable volume after reconstitutionApprox. 1.00 mL (factory estimate; project verification required)
Estimated priming lossApprox. 0.01–0.02 mL
Estimated residual volumeApprox. 0.05 mL at the cartridge neck
Best-fit programRepeated-treatment or replacement-cartridge evaluation
CustomizationElectroplated colour and surface finish, logo, label and packaging subject to review
Quality contextManufacturing-partner quality documentation reviewed during supplier qualification

Drug or application assessment

This platform may be evaluated for lyophilized peptides, biologics, hormones and other compatible two-component injectable projects. Application names describe screening contexts only and do not establish drug compatibility, intended use or regulatory approval.

Cartridge & needle compatibility

This configuration is quoted around a nominal 4 mL dual-chamber cartridge. Compatibility still depends on the cartridge drawing, chamber allocation, fill volumes, stopper positions, bypass geometry, closure configuration, intended needle and target delivered volume. Nominal capacity alone does not establish fit or performance.

OEM / ODM configuration

MechanismLoading and reconstitution sequence
AppearanceColor, finish, logo and artwork
Primary packDual-chamber cartridge assessment
Secondary packLabeling and packaging pathway

Validation & documentation

Project work may include cartridge-fit review, reconstitution-sequence assessment, mixing and visual-inspection criteria, dose-delivery verification, repeated-use lifecycle inputs, risk management and human-factors planning. Availability depends on the selected platform and agreed program.

Questions for platform selection

What is stored separately?Define the drug component, diluent or compatible liquid-liquid presentation.
What is the cartridge?Share drawings, chamber volumes, stoppers, bypass and tolerances.
How does it reconstitute?Define activation, mixing time, inspection criteria and allowable waiting time.
What is the target dose?Confirm delivered volume, dose range, increment, priming and residual volume.
Who will use it?Loading, replacement, training and feedback must fit the intended user.
Which market?Evidence and combination-product requirements vary by intended region.

Why evaluate this platform with Penacta

Penacta supports early platform screening while keeping the manufacturing relationship and technical boundaries clear. Device architecture, cartridge, formulation, reconstitution, dose profile, users and market pathway are reviewed as one project.

FAQ

What does reusable mean for this dual-chamber pen?

The pen body is retained for repeated use, while the project-matched medicine cartridge is replaced according to the treatment plan and validated instructions.

Which formulations may be evaluated with this platform?

The platform may be evaluated for a lyophilized drug plus diluent, or compatible liquid-liquid systems that must remain separated before use. Final suitability requires project-specific testing.

What are the documented cartridge and dose specifications?

The quoted configuration uses a nominal 4 mL dual-chamber cartridge, a 0.01–0.60 mL adjustable dose range and 0.01 mL increments. Final cartridge fit, dose accuracy and drug-device compatibility require project-specific verification.

What information is needed before sample evaluation?

Share the cartridge drawing, chamber volumes, stopper and bypass design, reconstitution sequence, viscosity after mixing, target dose, intended users and project stage.

Can the appearance and packaging be customized?

The housing is electroplated plastic, not metal. Electroplated colour, surface finish, logo, labeling and packaging can be discussed within the selected platform and project scope. Functional changes require separate technical review.